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ABSTRACT 
Context  Knee osteoarthritis (OA), a common cause of chronic pain and disability, has biomechanical and 
inflammatory origins and is exacerbated by obesity. 
Objective To determine whether a ≥ 10% reduction in body weight induced by diet, with or without exercise, 
would improve mechanistic (knee joint loads and inflammation) and clinical (pain, function, mobility, and health-
related quality of life) outcomes more than exercise alone in overweight and obese older adults with knee OA. 
Design, Setting, Participants IDEA was a single-blind, 18-month, randomized controlled trial conducted at 
Wake Forest University between July 2006 and April 2011, the final date of follow-up.  The diet and exercise 
interventions were center-based with options for the exercise groups to transition to a home-based program, or 
integrate the two for months 7-18.  Participants were 454 overweight and obese older (27 ≥ BMI ≤ 41kg.m-2, 
age ≥ 55 yrs) community-dwelling adults with pain and radiographic knee OA. 
Interventions Intensive diet-induced weight loss-plus-exercise (D+E), intensive diet-induced weight loss (D), 
or exercise (E). 
Main Outcome Measures An intention-to-treat analysis focused on the two primary outcomes, knee joint 
compressive force and plasma interleukin-6 (IL-6); secondary outcomes included self-reported pain (range, 0-
20) and function (range, 0-68), mobility, and health-related quality of life (HRQL, range, 0-100).  
Results  399 participants (88%) completed the study. Mean weight loss was: D+E, -10.6 kg (-11.4%); D, -8.9 
kg (-9.5%); E, -1.8 kg (-2.0%). After 18 months, mean (95%CI, Δ = pairwise difference) knee compressive 
forces were lower in D (2487 N; 2393,  2581) compared to E (2687 N; 2590, 2784, Δ E vs D = 200 N; 55, 345; p 
= 0.007). IL-6 concentrations were lower in D+E (2.7 pg.ml-1; 2.5,3.0) and D (2.7 pg.ml-1; 2.4, 3.0) compared to 
E (3.1 pg.ml-1; 2.9, 3.4, Δ E vs D+E = 0.39 pg
.ml-1; -0.03, 0.81; p = 0.007;  Δ E vs D = 0.43 pg
.ml-1; 0.01, 0.85, p = 
0.006). The D+E group had less pain (3.6; 3.2,4.1) and better function (14.1;12.6, 15.6) than the D group (4.8; 
4.3, 5.2, Δ D vs D+E =1.13, ppain = 0.001;17.4; 15.9, 18.9, Δ D vs D+E = 3.30, pfunction = 0.003) and E (4.7; 4.2, 5.1,     
Δ E vs D+E = 1.02; 0.33, 1.71, ppain = 0.004: 18.4; 16.9, 19.9, Δ E vs D+E = 4.29; 2.07, 6.50, pfunction = 0.0002). The 
D+E group (44.7; 43.4, 46.0) also had better physical HRQL scores than the E group (41.9, 40.5, 43.2, Δ E vs 
D+E =-2.81; -4.76, -0.86, p = 0.005). 
Conclusions Among overweight and obese adults with knee OA, after 18 months, participants in the D+E and 
D groups had more weight loss and greater reductions in IL-6 levels than those in the E group; those in the D 
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group had greater reductions in knee compressive force than those in the E group, and those in the D+E group 
had less knee pain and better function than those in the D and E groups. While these differences are relatively 
modest, their clinical promise warrants further study. 
Word count  494, Trial Registration: NCT00381290
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  OA is the leading cause of chronic disability among older adults, and knee OA the most frequent cause of 
mobility dependency and diminished quality of life. 1;2;3  Obesity as a major risk factor for knee OA was first 
documented in 1945 and subsequently widely verified.4-8  Current treatments for knee OA are inadequate; of 
patients treated pharmacologically, only about half experience a 30% pain reduction, usually without improved 
function.9 The few studies of long-term weight loss in obese adults with knee OA showed equally modest 
improvements.10;11     
Knee OA is considered an active disease process with joint destruction driven by both biomechanical and 
pro-inflammatory factors.12   In vitro13 and in vivo14 animal models elucidate specific mechanical and biological 
factors that affect cartilage degradation and tissue changes associated with cartilage growth and remodeling. 
However, clinical studies are the best vehicle for determining the physiological basis of the biomechanical 
factors that affect OA pathogenesis and treatment.12;15 
Considering the adverse effects of drug therapy,16-18 the limited efficacy of surgical intervention in mild-to-
moderate cases,19 and the long-term public health benefits of an effective treatment for OA and obesity-
related complications,20 we tested the hypothesis that achieving sustained, significant weight loss, with or 
without increased exercise, would reduce joint loading and inflammation and improve clinical outcomes more 
than increased exercise alone. This translational study compared the effects of diet-induced weight loss plus 
exercise (D+E), diet-induced weight loss only (D), and exercise-only (E) interventions on mechanistic (knee-
joint compressive force, IL-6) and clinical (pain, function, mobility, health-related quality of life) outcomes in 
overweight/obese adults with knee OA. 
 
METHODS 
 
Study Design 
 
 Intensive Diet and Exercise for Arthritis (IDEA) was a single-blind, single-center, 18-month, randomized 
controlled trial. Participants were randomized into one of three groups: D+E, D, or E. We designated E as the 
comparison group because our work21 indicated that aerobic walking or resistance training should be part of 
the standard-of-care for knee OA patients. Interventionists’ responsibilities were limited to exercise and 
dietary therapy interactions with patients (no data collection). Personnel responsible for data collection 
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without intervention responsibilities were blinded to group assignment. Trial design and rationale are detailed 
elsewhere.22  
Study Oversight 
   
IDEA was conducted at Wake Forest University and Wake Forest School of Medicine between July 2006 
and April 2011. The study was approved by the Human Subjects Committee of Wake Forest Health 
Sciences. Informed consent was obtained in writing from all participants.  
Study Sample 
 
The sample consisted of ambulatory, community-dwelling persons age  55 years with: (1) Kellgren-
Lawrence (KL) grade 2 or 3 (mild or moderate) radiographic tibiofemoral OA or tibiofemoral plus 
patellofemoral OA of one or both knees,23 (2) pain on most days due to knee OA, (3) 27 ≤ Body Mass Index 
(BMI) ≤ 41 kg.m-2, and (4) a sedentary lifestyle (< 30 min
.
wk-1 of formal exercise for the past 6 months). 
Participants maintained and adjusted their usual medications as needed with their physician’s consent. 
Eligibility, sample size calculations, and screening measurements are detailed elsewhere.22  Race/ethnicity 
was determined by self-report. 
Participants were recruited between November 2006 and December 2009.  Eligibility was determined by 
initial phone screen and two in-person screening visits.22  A stratified-block randomization method was used 
to assign all eligible persons to one of the three intervention arms, stratified by BMI and gender.   
 
Interventions  
 
 The D group received the weight loss intervention, the E group received the exercise intervention, and 
the D+E group received both.  
 Intensive weight loss intervention.  The goal of this intervention was a mean group loss of at least 10% of 
baseline weight, with a desired range between 10% and 15%. The diet was based on partial meal 
replacements, including up to 2 meal-replacement shakes per day (Lean Shake®, provided by General 
Nutrition Centers, Inc., Pittsburgh, PA.). For the third meal, participants followed a weekly menu plan and 
recipes that were 500-750 kcals, low in fat, and high in vegetables. Daily caloric intake was adjusted 
according to the rate of weight change between intervention visits. 
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 The initial diet plan provided an energy-intake deficit of 800-1000 kcals.d-1 as predicted by energy 
expenditure (estimated resting metabolism x 1.2 activity factor) with at least 1100 kcals for women and 1200 
kcals for men. The calorie distribution goal was 15-20% from protein, < 30% from fat, and 45-60% from 
carbohydrates, consistent with the Dietary Reference Intakes for Energy and Macronutrients 24 and 
successful weight-loss programs.25 As follow-up progressed, fewer meal replacements were consumed. Body 
weight was monitored weekly or biweekly during nutrition education and behavioral sessions: from months 1-
6, one individual session and 3 group sessions per month, and from months 7-18, biweekly group sessions 
and an individual session every 2 months.  
 Exercise Intervention. The exercise intervention was conducted for 1 hour 3 d.wk-1 for 18 months.  During 
the first 6 months, participation was center-based. After 6-month follow-up (FU6) testing and a 2-week 
transition phase, participants could remain in the facility program, opt for a home-based program, or combine 
the two. The program consisted of aerobic walking (15 min), strength training (20 min), a second aerobic 
phase (15 min), and cool-down (10 min).  
Techniques to improve adherence. Diet and exercise interventionists were trained in behavioral techniques 
based on social cognitive theory and group dynamics.26;27  Adherence data were reviewed regularly to identify 
participants who needed additional counseling. Participants in both the D and E interventions self-monitored by 
completing daily logs. A behavioral “toolbox” for participants in the D+E and D groups who had difficulty 
achieving the weight-loss goal included  additional individual and group counseling, social support, and 
incentives. 
Measurements and Procedures 
All participants were tested at baseline, FU6, and FU18. An initial symptom-limited, maximum exercise 
stress test excluded anyone with severe manifestations of coronary heart disease. The Modified Mini-Mental 
State Exam (3MSE) screened for cognitive deficiencies.28   
Knee Joint Load.  Bone-on-bone peak tibiofemoral (knee) compressive force was the primary measure of 
knee joint loading. Detailed description of instruments and calculation of knee joint compressive force can be 
found on the on-line supplement.   
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Plasma IL-6. Blood samples were collected in the early morning after a 10-hour fast at baseline, FU6, and 
FU18.  The 6- and 18-month samples were collected at least 24 hours after the last acute bout of exercise 
training (D+E and E groups) and sampling was postponed (1-2 weeks after recovery from symptoms) in the 
event of an acute respiratory, urinary tract, or other infection.  All blood was collected, processed, divided into 
aliquots, and stored at -80oC until analysis.  
 The inflammation measure was plasma IL-6 pg.ml-1. This cytokine is implicated in OA pathogenesis 
and showed significant improvement with weight loss in the Arthritis Diet and Activity Promotion Trial 
(ADAPT).29 All samples were measured in duplicate using enzyme-linked immunosorbent assays 
(Quantikine ELISA kits R&D Systems, Minneapolis, MN) with the average used for data analyses.  
Pain. The Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) pain subscale was 
used to measure self-reported pain.30  Participants indicate on a scale from 0 (none) to 4 (extreme) the 
degree of pain experienced performing daily living activities in the last 48 hours due to knee OA. Total scores 
for the 5 items range from 0-20; higher scores indicate greater pain.30;31   Function. Individual scores on the 
17 items of the WOMAC self-reported function subscale were added to generate a summary score ranging 
from 0 to 68; higher scores indicate poorer function.  A minimally clinically important difference of at least 
20% improvement from baseline is required for both pain and function.32  
Mobility. We measured gait speed (m.s-1) and 6-minute walk distance (m).33  
Weight, height, BMI. Weight, height, and BMI were obtained at baseline, FU6, and FU18 using standard 
techniques. D+E and D participants were weighed at each scheduled nutrition education and behavioral 
session.  
Body composition. Whole body lean mass (LM) and fat mass (FM) were measured at baseline and FU18 
by dual x-ray absorptiometry using a fan-beam scanner (Delphi A™, Hologic, Waltham, MA) and the 
manufacturer’s recommendations for patient positioning, scanning, and analysis.  
Health-related quality of life (HRQL). SF-3634 was used to measure HRQL using two broad summary 
scores: physical and mental health, scaled from 0 (worst) to 100 (best).  
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X-ray. We used bilateral, posterioranterior, weight-bearing knee x-rays to identify tibiofemoral OA and 
sunrise views to identify patellofemoral OA. To visualize the tibiofemoral joint, we used a positioning device to 
flex knees 15 degrees, with the beam centered on the joint space. 
Modified Mini-Mental State Exam (3MSE). This quantitative assessment of cognitive functioning examines 
orientation to time and place, recall, short-term memory, and arithmetic ability. Anyone scoring below 70 at 
baseline was ineligible.28 
Statistical Analysis   
Primary outcomes for IDEA were IL-6 and knee compressive force.  IL-6 was log-transformed for sample 
size calculations and analyses.  Standard deviations were obtained from the ADAPT10 study which measured 
the same outcomes in a similar population.  The sample size of 150 participants per group was calculated 
based on both primary outcomes to obtain 80% power to detect a 20% difference in IL-6 group mean ratios at 
month 18 and a 15% between group mean difference in knee compressive force at the 0.008 significance level 
adjusted for 2 outcomes, 3 treatment groups, and 80% retention.  This sample size also provided 80% power 
for mean differences in secondary outcomes of 2.9 for WOMAC function and 1.0 in WOMAC pain at the 0.0167 
(3 treatment groups) significance level. 
Intention-to-treat analyses were conducted with SAS v9.2 (SAS Institute, Cary, NC). Two-sided nominal p-
values are reported. One-way analyses of variance and chi-square tests addressed differences in baseline 
characteristics among groups. The interventions’ effects on knee compressive forces, IL-6, WOMAC pain and 
function, walk speed, 6-minute walk, and SF-36 were determined using mixed model regression analyses 
adjusted for IDEA stratification factors (BMI, gender, and baseline values). Analyses included all follow-up data, 
and intervention effects were estimated at each follow-up visit. A contrast for the intervention effect at 18 
months was tested in each model, using the E group as the reference group.  Effect sizes were calculated by 
subtracting the E mean from the D+E and D least-squared means and dividing by their pooled standard 
deviations.  Unadjusted percent change at FU18 for each group was obtained by subtracting the baseline 
mean from the 18-month mean and dividing by the baseline mean. When the overall FU18 p value was ≤ 0.025 
for the primary outcomes, specific pairwise differences were noted, with the significance level adjusted for six 
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comparisons (p≤ 0.008).  For the secondary outcomes, the significance levels were 0.05 and 0.0167 (3 
treatment groups).  
To assess whether our results were biased due to missing data, we performed a sensitivity analysis using 
multiple imputation for all 454 randomized individuals. We imputed 50 fully observed datasets with complete 
data at 6 and 18 month visits, analyzed each dataset using our previously stated analytic protocol, and 
aggregated the results. The imputation and aggregation were performed using PROC MI and PROC 
MIANALYZE, respectively, in SAS v9.3. Data from the multiple imputation analyses are presented below and 
the intention-to-treat completers-only analyses are shown in the on-line supplement.   
The dose-response relationship between each outcome variable and continuous and categorical weight 
change (<5%, 5-9.9%, ≥ 10%) was assessed using mixed model regression analyses, controlling for BMI, 
gender, baseline values, and group assignment. The weight loss categories reflect the weight loss goals of 
≥5% for ADAPT and ≥10% for IDEA.10;22 
RESULTS 
Retention and Adherence 
   Figure 1 and Table 1 show eligibility criteria, characteristics, and progress of the randomized cohort. Of 
the 454 participants, 399 (88%) completed the study (returned for FU18). Retention did not differ significantly 
among the groups (E, 89%; D, 85%; D+E, 89%), and non-completers did not differ significantly from 
completers in terms of age, sex, race, number of comorbidities, initial radiographic score, knee pain, or 
physical function. 
 Adherence to exercise (number of sessions completed/number scheduled) for the E group was 66% for the 
first 6 months and 54% for 18 months; for the D+E group, it was 70% and 58%, respectively. Adherence to the 
diet intervention (number of individual and class sessions attended/number scheduled) was 61% for the D 
group and 63% for the D+E group. Three non-serious adverse events related to the trial included a muscle 
strain and 2 trips/falls during exercise sessions that resulted in soreness and bruising. The external safety 
monitor determined that 10 serious adverse events were unrelated to the study (eTable 1). Seven participants 
underwent surgery during the study: E, 1 knee surgery, 3-knee replacements; D+E, 1-foot, 1-gall bladder, 1-hip 
replacement. All but the knee surgery patient returned to the study after surgery. 
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Weight Loss and Body Composition 
 Both diet groups lost significantly (p < 0.0001) more weight than the E group (Table 2). The D group lost 8.9 
kg (9.5%) over 18 months; the D+E group lost an average of 10.6 kg (11.4%). Neither group regressed toward 
baseline values (see eFigure 1). The E group lost 1.8 kg, or 2.0% of baseline body weight. At baseline, 79.3% 
of all participants had a BMI ≥ 30 kg.m-2.  At FU18, this was reduced to 55.5% including E = 69.0%, D = 54.6%, 
and D+E = 43.3%. 
 Total fat mass was significantly less in both diet groups relative to the E group after 18 months (p <  
0.0001). Fat mass remained essentially unchanged (-0.4 kg) in the E group, while decreasing 6.5 kg (18%) and 
4.8 kg (13%) at FU18 in the D+E and D groups, respectively. The D+E and D groups lost significantly more 
lean mass than the E group (p<0.0001), but the percent of lean mass at 18 months did not differ among the 
three groups. 
Knee Joint Load and Inflammation   
 Evaluation of peak knee compressive force (our biomechanical outcome measure of joint loading) at 18 
months demonstrated that the E group had decreased joint loading by 148 N (5%), D by 265 N (10%), and 
D+E by 230 N (9%) (Table 3). Of the pairwise between group comparisons, the E vs D comparison had the 
greatest difference in compressive force of 200 N (p=0.007; 55,345). The difference between the E vs D+E 
groups and the D vs D+E groups were not significant (Table 4).   
 Plasma IL-6 also differed significantly among the groups (p = 0.0075); pairwise between group comparisons 
revealed that the differences in the D+E and D  groups relative to E were 0.39 pg.ml-1 (-0.03,0.81;p=0.007) and 
0.43 pg.ml-1(0.01,0.85;p=0.006) respectively (Tables 3 and 4).   
Pain and Function  
 Pairwise between group comparisons of WOMAC pain and function at 18 months revealed that the D+E 
group had less pain relative to the E (1.02; 0.33,1.71;p=0.004) and D (1.13; 0.44,1.82; p=0.001) groups (Table 
4, Figure 2). Post-hoc analysis revealed that 38% of the D+E group reported little or no pain after 18 months 
with scores of 0 or 1 (0-20) compared with 20% and 22% of the participants in the D and E  groups, 
respectively.  
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  Pairwise between group comparisons revealed that WOMAC function score was significantly better in the 
D+E group relative to the E group (4.29; 2.07,6.50;p = 0.0002). Similarly, D+E had better function than D (3.30; 
1.09, 5.51, p=0.003).  The E vs D comparison showed no significant difference (Table 4). 
Mobility and Health-Related Quality of Life  
 At 18 months, the D+E group walked 0.04 m.s-1 faster relative to the E group (-0.07, -0.02; p = 0.003).  The 
E vs D and D vs D+E comparisons were not significant. 6-minute walk distance was 21.3 m farther in the D+E 
group relative to the E group (-36.3,-6.4;p=0.005).  The D+E group also walked 41.5 m farther than the D 
group (-56.4,-26.6;p<0.0001), and E walked further than D (20.2 m; 5.0, 35.4; p = 0.009).  The greatest 
difference in the SF-36 physical subscale was 2.81 units in D+E relative to the E group (-4.76,-0.86; p=0.005). 
Changes in the SF-36 mental subscale did not reach significance between any groups (Tables 4).  
Sensitivity Analysis   
Results from the intention-to-treat completers-only analyses that did not use multiple imputations are 
shown in eTables 2-3.  Pairwise comparisons for knee joint compressive load, IL-6, pain, and function were 
statistically unchanged between the intention-to-treat and multiple imputation analyses. Comparisons between 
D+E and E for 6-minute walk distance and SF-36 physical subscale reached statistical significance only in the 
multiple imputation analysis (D+E was better than E, p = 0.005). 
Dose Response to Weight Loss   
 We examined the relationship of percent weight change to 18-month mean [SE] mechanistic and clinical 
outcomes adjusted for intervention, BMI, gender, and baseline values. Independent of group assignment, the 
cohort was divided into 3 categories based on 18-month weight loss: high (H): -32.5% to -10.1%; medium (M): 
-9.9% to -5.0%, and low (L): -4.9% to +9.9%. We found significant weight-change dose-response effects in 
knee compressive force, IL-6, pain, and function;  participants in the high category had significantly lower joint 
loads, less systemic inflammation and pain, and better function at FU18 (eTable 4). 
COMMENT   
In this translational study of weight loss and exercise among overweight and obese adults with knee OA, 
we found that after 18 months mean weight loss was greater in the D+E group and the D group compared 
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with the E group.  In addition, when compared with the E group, the D+E group had less inflammation, less 
pain, better function, faster walking speed, and better physical health related quality of life.   
Primary Outcomes   
Peak knee compressive forces decreased and walking speeds increased in all three groups after the 18-
month intervention period. In pairwise between group comparisons, peak knee compressive forces were 200 
N (45 lb) per step less in the D group than in the E comparator group (Table 4).  The clinical importance of 
this difference is unknown, although it appears that weight loss reduces knee-joint loading even as preferred 
walking speed increases.   
Whether inflammation constitutes a separate OA disease pathway, or instead is the downstream result of 
chronic excessive biomechanical stress is debated.12;35  Systemic inflammation markers, including IL-6, 
distinguished knee or hip OA patients from controls,36 and higher systemic levels of IL-6 have been 
associated with increased odds of developing knee OA.37  Diffusion of such cytokines from the synovial fluid 
into the cartilage could contribute to cartilage matrix loss by stimulating chondrocyte catabolic activity and 
inhibiting anabolic activity.12;38 In addition to these direct effects on the joint, inflammatory mediators can 
affect muscle function and lower the pain threshold.39 IL-6 concentrations less than 2.5 pg.ml-1 have been 
shown to reduce the risk of mobility disability and improve markers of metabolic syndrome.40 Participants in 
all 3 groups exceeded this level (mean = 3.1 pg.ml-1) at baseline, with significant improvements in D+E and D 
relative to E at 18 month follow-up.  Our study was powered to detect a 15% and 20% difference in knee 
compressive force and IL-6, but found differences of approximately 8% and 14%, respectively.  Results need 
to be interpreted with this in mind. 
Secondary Outcomes   
With regard to pain, between group differences in WOMAC score were 1.02 and 1.13 units in the D+E vs 
E and the D+E vs D groups, with D+E having less pain. The D+E group reached an adjusted 45% (3.0 
points) and 42% (10.3 point) within group change in pain and function at 18 months, respectively.  This 
within-group pain reduction and a similar improvement in function may be clinically important; however, the 
difficulty in interpreting the meaning of between- and within- group changes, especially in pain, must be 
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acknowledged.41  Hence, the clinical significance of 1.02- and 1.13-point between group differences in the 
WOMAC pain scale remains uncertain.   
Post-hoc analysis revealed that nearly 40% of D+E participants had WOMAC pain scores of 0-1 (no or 
little pain) at 18 month follow-up compared to 20% of the D and E groups; pain worsened from baseline in 
10% of the D+E group compared to 22% in the D and 28% in the E groups. The D group, which had similar 
decreases in joint loads and inflammation, experienced only half the D+E pain reduction.  Reasons for this 
finding are unclear. The E group’s pain reduction, despite increased joint loads, inflammation, and walk 
speed, may indicate psycho-physiological effects of exercise on the central42 and peripheral nervous 
systems.43 
Patients in our cohort reported relatively mild pain at baseline (averaging 6.5 on a 0-20 scale), similar to 
participants in previous long-term OA clinical trials.10;11;44 This entry level may have been an advantage 
because lack of adherence due to extreme pain was uncommon, but it left little room for improvement.  
Despite use of an active comparison group with level 1 evidence of efficacy,45 the D+E group had better 
clinical outcomes (i.e., pain, function, and mobility), with an effect size (Cohen’s d)46 for pain of 0.4. 
Adherence to exercise for the D+E and E groups was 70% and 66%, respectively, during the first 6 months of 
center-based activity.  As participants incorporated home-based exercise after month 6, adherence 
decreased to 58% and 54% after 18 months. The D+E group’s improvement in function and mobility was 
modest but significantly greater than either the D or E groups’ and greater than that achieved by the ADAPT 
D+E group.10  Improvements also exceeded those observed in a randomized controlled trial that compared a 
very low-energy diet to an attention control group11 in which function improved in the diet group at 3-month 
follow-up but regressed toward baseline values by 12 months.  We attribute our results to challenging yet 
attainable weight-loss and exercise goals with a social cognitive behavioral framework.                                                                                                                                                                               
Walk speed and 6 min walk distance, measures of mobility, were below normative values for healthy older 
adults at baseline.47;48  At FU18, the D+E group exceeded these normative values, with significant pairwise 
differences relative to the E and D groups (see Table 4).  Himann et al.47 found that walking speed decreased 
1-2% per decade of adult life until age 62, when the decline was a startling 12-16% per decade. Our cohort 
reversed this trend by increasing their walking speed and 6 minute walk distance, D+E significantly more than 
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the E and D groups. These improvements, in part, may have been due to the significant reduction in knee 
pain. The D+E group significantly improved the physical health dimension of HRQL relative to the E group 
with a pairwise difference of 2.81 and an improvement from baseline of 8 units.  A minimally important 
improvement from baseline of 4.11 in the physical subscale has been reported for patients with psoriatic 
arthritis.49  There were no between group difference in mental subscale scores. 
A multiple imputation analysis revealed minimal differences from our original intention-to-treat analysis, 
indicating the strength of the primary analysis.  This was due to the low drop-out rate relative to similar studies. 
21;50  Drop-out did not occur differentially with respect to randomization group, gender, or baseline BMI ( 
p>0.05).   
Independent of group assignment, participants who lost ≥ 10% of body weight improved function and 
reduced knee compressive force, systemic IL-6 concentrations, and pain more than those who lost 5-9.9% or 
<5% of their baseline weight. These data are consistent with the NIH recommendation for overweight and 
obese adults to lose 10% of baseline weight as an initial goal.20  Weight-loss programs for older adults are not 
without risks. In addition to fat mass, weight loss reduces lean mass, which is associated in older adults with 
muscle weakness, greater risk of falls and injury, and loss of independence and mobility, although exercise can 
attenuate it.51   Both diet groups lost substantial fat mass (D+E, -10.6 kg, -18%; D, -8.9 kg, -13%) and -4.7 kg (-
9%) and -4.2 kg (-8%), respectively, of lean mass. However, relative to total body weight at FU18, lean mass 
actually increased 3% in the D+E group and 2% in the D group.   
This study has several limitations. Patients in this study had mild-to-moderate radiographic knee OA at 
baseline (KL scores of 2-3) and similar levels of knee pain.  Whether patients with more severe knee OA (KL 
score = 4) and higher levels of pain would benefit from this long-term intervention is unknown. The IDEA  trial 
also benefited from its single-site design, as single-site studies tend to have larger treatment effects than multi-
center trials.52  The musculoskeletal model used to calculate knee compressive forces has several limitations. 
Several knee ligaments are not included; it assumes that the hip flexors and hip abductors do not co-contract 
during stance; and its lumped muscle model design cannot distinguish between smaller muscle anatomical 
units.  Nonetheless, we have used this model extensively53-56 and as we recently demonstrated55 our muscle 
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and joint force predictions are in excellent agreement with those based on a variety of other models57;58  and 
from measured forces from instrumented knee joint prostheses.59;60  
OA and other obesity-related diseases place an enormous physical and financial burden on the US 
healthcare system.61 The estimated 97 million overweight and obese Americans are at substantially higher 
risk for many life-threatening and disabling diseases, including OA.20  Our data suggest that intensive weight 
loss may have both anti-inflammatory and biomechanical benefits; when combined with exercise, compliant 
patients can safely achieve a mean long-term weight loss of >10% with associated improvement in symptoms 
greater than with either intervention alone.  
Among overweight and obese adults with knee OA, after 18 months, participants in the D+E and D 
groups had more weight loss and greater reductions in IL-6 levels than those in the E group; those in the D 
group had greater reductions in knee compressive force than those in the E group; and those in the D+E 
group had less knee pain and better function than those in the D and E groups and improved physical HRQL 
than those in the E group. While these differences are relatively modest, their clinical promise warrants 
further study. 
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Figure legends 
 
Figure 1.  Participant progress through the Intensive Diet and Exercise for Arthritis (IDEA) trial. 
 
Figure 2.  Mean (±95%CI) unadjusted Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) pain scores across the 18-month intervention period.  
eFigure 1.  Mean (95%CI) month-by-month weight loss of the D and D+E groups.  If a participant was absent 
on weigh-in day the weight from the previous month was carried forward for that month. 
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Table 1. Mean (SD) demographic and clinical characteristics of the study participants at baseline.
Baseline Characteristics Overall Exercise Diet Diet + Exercise P Value 
 (N = 454) (N = 150) (N = 152) (N = 152)  
Age (yrs) 66 (6) 66 (6) 66 (6) 65 (6) 0.86 
Female  No. (%) 325 (72) 108 (72) 108 (71) 109 (72) 0.98 
Nonwhite  No. (%) 85 (19) 30 (20) 25 (16) 30 (20) 0.68 
Weight (kg) 93 (14.7) 92 (14.5) 93 (15.2) 93 (14.4) 0.82 
Height (m) 1.66 (0.09) 1.66 (0.09) 1.66 (0.09) 1.66 (0.09) 0.91 
BMI (kg/m
2
) 33.6 (3.7) 33.5 (3.7) 33.7 (3.8) 33.6 (3.7) 0.90 
Annual household income No. (%)     0.63 
  <$20 000 40 (9) 14 (9) 15 (10) 11 (7)  
  $20 000-$34 999 68 (15) 27 (18) 21 (14) 20 (14)  
  $35 000-$49 999 86 (19) 32 (22) 25 (17) 29 (20)  
 >$50 000 253 (57) 75 (60) 90 (51) 88 (59)  
Education  No. (%)     0.35 
 ≤ High School 72 (16) 29 (19) 21 (14) 22 (14)  
 >High School 380 (84) 120 (81) 130 (86) 130 (86)  
Comorbid illness, No. (%)      
 Obesity (BMI ≥ 30 kg
.
m
-2
) 360 (79) 118 (79) 121 (80) 121 (80) 0.97 
Arthritis in other joints 265 (61) 92 (63) 84 (57) 89 (62) 0.59 
 Hypertension 273 (61) 89 (60) 93 (63) 91 (61) 0.85 
 Cardiovascular heart disease 42 (10) 12 (8) 19 (13) 11 (8) 0.22 
 Diabetes 59 (13) 18 (12) 18 (12) 23 (15) 0.64 
Kellgren-Lawrence grade 2.56 (0.59) 2.53 (0.56) 2.58 (0.60) 2.59 (0.60) 0.64 
WOMAC function (range 0-68) 24.2 (10.9) 23.1 (10.3) 24.8 (10.4) 24.6 (11.7) 0.33 
WOMAC pain (range 0-20) 6.5 (3.1) 6.1 (2.9) 6.6 (3.0) 6.7 (3.4) 0.24 
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Table 2.  Mean (95%CI) body composition values for the three groups across the 18-month intervention period. 
 
 
aD+E and D < E 
 
 
    
  
 Exercise Diet Diet + Exercise P 
 Months Months Months  
 0 6 18 Δ 0 6 18 Δ 0 6 18 Δ  
Weight (kg) 92.3 92.4 90.5 -1.8 93.4 85.5 84.5 -8.9 93.0 84.3 82.4 -10.6 <0.0001
a
 
   CI 89.9,94.6 89.7,95.2 87.7,93.2 -5.7,1.8 91.0,95.8 82.8,88.1 81.8,87.1 -12.4,-5.3 90.6,95.3 81.8,86.8 79.7,85.1 -14.1,-7.1  
    N for weight 150 122 115  152 115 120  152 133 121   
Fat Mass (kg) 37.0  36.7 -0.4 36.3  31.5 -4.8 36.8  30.3 -6.5 <0.0001
a
 
  CI 35.7,38.4  34.9,38.4 -2.5,1.8 34.9,37.6  29.7,33.3 -7.0,-2.6 35.5,38.1  28.6,32.0 -8.6,-4.4  
% Fat Mass 40  41 1 40  38 -2 40  37 -3  
Lean Mass (kg) 56.1  53.5 -2.6 55.3  51.1 -4.2 55.6  50.8 -4.7 <0.0001
a
 
  CI 54.0,58.1  51.2,55.7 -5.7,0.5 53.2,57.6  48.8,53.4 -7.4,-1.1 53.6,57.6  48.7,53.0 -7.7,-1.8  
% Lean Mass 60  59 -1 60  62 2 60  63 3  
  N for fat/lean 131  94  128  88  136  102   
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Table 3. IDEA outcomes from multiple imputation-based model that used 50 multiply imputed datasets per variable. Mixed effects model 
adjusts for baseline BMI, gender, and baseline values. Knee compressive force and IL-6 significance levels were set at 0.025; for 
secondary outcomes the significance level was 0.05.  
 
 
#D+E and D < E; *D+E<E and D; †D+E>E and D; ‡D+E>E and D, E>D. "D+E>E   
 Exercise Diet Diet + Exercise P 
 Months  Month 18 
adjusted 
Months  Month 18 
Adjusted 
 
Months  Month 18 
Adjusted 
 
 
 0 6 18 Δ  
(%)  
0 6 18 Δ  
(%) 
0 6 18 Δ 
 (%) 
 
Comp 
Force (N) 
2768 2877 2620 
--148 
(-5) 
2687 2626 2466 2361 
-265 
(-10) 
2487 
 
2655 2593 2425 
-230 
(-9) 
2543 
 
0.019
#
 
95% CI 2612,2925 2720,3034 2475,2765  2590,2784 2480,2773 2333,2598 2242,2481  2393,2581 2506,2804 2460,2725 2306,2544  2448,2637  
IL-6 
(pg
.
mL
-1
) 
3.0 2.9 3.0 
0.1 
(0) 
3.1 3.2 2.7 2.7 
-0.5  
(16) 
2.7 
 
3.2 2.8 2.7 
-0.5 
(15) 
2.7 
 
0.0075
#
 
95% CI 2.6, 3.3 2.6, 3.3 2.7, 3.3  2.9,3.4 2.8, 3.6 2.4,3.1 2.3,3.0  2.4,3.0 2.9, 3.6 2.5,3.2 2.4, 3.1  2.5,3.0  
Pain 6.1 4.5 4.4 
-1.7 
(-28) 
4.7 6.6 4.9 4.8 
-1.8 
(-27) 
4.8  6.7 4.6 3.7 
-3.0 
(-45) 
3.6 
 
0.002
*
 
95% CI 5.6,6.6 4.0,5.1 3.9,4.9  4.2,5.1 6.1, 7.1 4.4,5.3 4.2, 5.3  4.3,5.2 6.1, 7.2 4.1,5.1 3.1,4.2  3.2,4.1  
Function 23.1 17.7 17.6 -5.5 
(-24) 
18.4 24.8 18.3 17.7 
-7.1 
 (-29) 
17.4  24.6 16.5 14.2 
-10.3 
(-42) 
14.1 
 
0.0004
*
 
95% CI 21.4,24.8 15.9,19.5 15.8,19.4  16.9,19.9 23.2, 26.5 16.6,20.0 15.7,19.8  15.9,18.9 22.7, 26.5 14.7,18.3 12.4,16.1  12.6,15.6  
WalkSpeed 
(m
.
s
-1
) 
1.23 1.32 1.30 
0.07 
(6) 
1.29 1.18 1.25 1.27 
0.09 
 (8) 
1.29  1.20 1.32 1.33 
0.12 
(10) 
1.33 
  
0.008
†
 
95% CI 1.20,1.26 1.29,1.35 1.27,1.33  1.27,1.31 1.15, 1.21 1.22,1.28 1.25,1.30  1.27,1.31 1.17, 1.23 1.28,1.35 1.29,1.36  1.31,1.35  
6 minute 
walk (m) 
480 533 525 
45 
(9) 
525 475 505 502 
26  
(6) 
505  467 537 537 
70 
(15) 
546 
  
<0.0001
‡ 
95% CI 466,495 518,547 511,540  515,535 462, 488 492,518 488,515  495,515 453-481 522,552 520,553  536,556  
SF-36 
Physical 
36.8 41.5 42.0 
5 
(14) 
41.9 36.0 41.8 42.0 
6  
(17) 
42.4  36.6 43.5 44.7 
8 
(23) 
44.7 
 
0.013" 
95% CI 35.3,38.2 39.9,43.1 40.3,43.6  40.5,43.2 34.5, 37.4 40.2,43.4 40.3,43.7  41.1,43.7 35.1, 38.1 41.9,45.0 43.1,46.2  43.4,46.0  
SF-36 
Mental 
56.5 56.1 55.4 
-1.0 
(-2) 
55.6 55.9 55.0 54.9 
-1.0  
(-2) 
55.3  57.2 56.9 56.1 
-1.1 
 (-2) 
55.8 
 
0.853 
95% CI 55.1,57.8 54.8,57.5 54.0,56.8  54.4,56.7 54.5, 57.2 53.6,56.4 53.6,56.1  54.2,56.5 56.2, 58.3 55.7,58.2 54.9,57.2  54.7,57.0  
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Table 4. Pairwise between group differences (mean and 95% confidence interval) at 18-month follow-up for primary and secondary 
outcomes using multiple imputation adjusted for baseline BMI, gender, and baseline values.  Knee compressive force and IL-6, 
significance levels were set at a 0.008; for secondary outcomes the significance level was 0.0167.  
 
 
 
 
 
 
 
 
 
 
*p-value from the log-adjusted variable comparisons. 
 
  
 Exercise vs. Diet p Exercise vs. Diet + Exercise p Diet vs. Diet + Exercise p 
Knee Comp Force N 200 (55,345)  0.007 144 (1,287)  0.05 -56 (-199, 88)  0.45 
IL-6 pg
.
mL
-1
 0.43 (0.01, 0.85)  0.006* 0.39 (-0.03, 0.81)  0.007* -0.04 (-0.47, 0.40)  0.98* 
Pain -0.11 (-0.81, 0.59)  0.76 1.02 (0.33, 1.71)  0.004 1.13 (0.44, 1.82)  0.001 
Function 0.98 (-1.24, 3.20) 0.38 4.29 (2.07, 6.50) 0.0002 3.30 (1.09, 5.51) 0.003 
Walk Speed (m
.
s
-1
) -0.01 (-0.04, 0.02) 0.59 -0.04 (-0.07, -0.02) 0.003 -0.04 (-0.07, -0.01) 0.02 
6 minute walk (m) 20.2 (5.0, 35.4) 0.009 -21.3 (-36.3, -6.4) 0.005 -41.5 (-56.4, -26.6) <0.0001 
SF-36 Physical -0.55 (-2.53, 1.43) 0.59 -2.81 (-4.76, -0.86) 0.005 -2.26 (-4.30, -0.23) 0.03 
SF-36 Mental 0.23 (-1.47, 1.93) 0.79 -0.26 (-1.95, 1.43) 0.76 -0.49 (-2.25, 1.26) 0.85 
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eTable 1.  Serious adverse events.  All were unrelated to the study. 
 
 
Serious Adverse Event Completed Study (Y/N) Diet Exercise Diet + Exercise 
Heart Palpitations Y 
 
x 
 ALS N 
  
x 
Stroke N 
  
x 
Lung Hypertension Y 
 
x 
 Lung Infection Y 
  
x 
Cancer Y 
  
x 
Cancer N x 
  Cancer Y 
 
x 
 Cancer N 
  
x 
Staph Infection Y 
  
x 
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eTable 2. Intention-to-treat completers-only analysis. Unadjusted mean (95%CI) mechanistic and clinical outcomes at baseline (0), and 6 
and 18-month follow-up by group and 18-month outcomes adjusted for gender, BMI, and baseline values. The adjusted data were used to 
determine between-group P values and effect sizes. Knee compressive force and IL-6 significance levels were set at 0.025; for secondary 
outcomes the significance level was 0.05.                    
 
 Δ = 18-month follow-up minus baseline for participants that completed the study (i.e., returned for 18-month testing)    
 ES = Effect size compared to Exercise-only group 
 #D+E and D < E; *D+E<E and D; †D+E>E and D; ‡D+E>E and D, E>D.  All P values and ES based on 18-month adjusted means. 
 For more detail on pairwise comparisons see eTable 3.  
 
 
 
 Exercise Diet Diet + Exercise P 
 Months – unadjusted  Month 18 
adjusted 
Months - unadjusted Month 18 
Adjusted 
[ES] 
Months - unadjusted Month 18 
Adjusted 
[ES] 
 
 0 6 18 Δ  
(%)  
0 6 18 Δ  
(%) 
0 6 18 Δ 
 (%) 
 
Comp 
Force (N) 
2816 2946 2662 
--154 
(-5) 
2728 2676 2478 2377 
-299 
(-11) 
2526 
[-0.4] 
2690 2599 2444 
-246 
(-9) 
2585 
[-0.3] 
0.019
#
 
95% CI 2657,2975 2800,3092 2513,2810  2622,2834 2509,2843 2326,2629 2224,2531  2417,2634 2528,2852 2454,2744 2296,2592  
2479, 
2690 
 
N 133 119 111  111 125 109 103  103 134 122 110  111  
IL-6 
(pg
.
mL
-1
) 
2.9 2.9 3.0 
0.1 
(3) 
3.2 3.2 2.7 2.7 -0.5 (16) 
2.7 
[-0.3] 
3.3 2.9 2.8 
-0.4 
(13) 
2.7 
[-0.3] 
0.0005
#
 
95% CI 2.5, 3.2 2.5, 3.3 2.6, 3.4  2.89,3.51 2.8, 3.6 2.3,3.0 2.3,3.0  2.34,2.97 2.9, 3.7 2.5,3.2 2.4, 3.1  2.39,3.01  
N 133 125 117  117 128 113 114  114 137 129 119  119  
Pain 6.0 4.4 4.3 
-1.7 
(-28) 
4.3 6.4 4.8 4.8 
-1.6 
(-25) 
4.8 [0.2] 6.7 4.6 3.3 
-3.4 
(-51) 
3.3 
[-0.4] 
0.0001
*
 
95% CI 5.5,6.4 3.8,5.0 3.8,4.9  3.8,4.9 5.9, 6.9 4.2,5.4 4.3, 5.4  4.3,5.3 6.2, 7.3 4.1,5.2 2.7,3.9  2.8,3.8  
N 127 119 127  127 124 115 124  124 138 130 129  129  
Function 22.5 17.2 17.4 -5.1 
(-23) 
17.2 24.3 18.3 17.8 -7.0 (-29) 17.3 [0.0] 24.5 16.4 13.0 
-11.5 
(-47) 
13.0 
 [-0.5] 
0.0001
*
 
95% CI 20.8,24.3 15.2,19.2 15.4,19.4  15.6,18.8 22.4, 26.2 16.3,20.3 15.8,19.8  15.7,18.8 22.5, 26.6 14.5,18.3 11.1,15.0  11.5,14.6  
N 128 119 127  127 124 116 124  124 138 131 129  129  
WalkSpeed 
(m
.
s
-1
) 
1.24 1.33 1.30 
0.06 
(5) 
1.30 1.20 1.26 1.28 0.08 (7) 1.30 [0.0] 1.21 1.32 1.34 
0.13 
(11) 
1.34 
 [0.3] 
0.013
†
 
95% CI 1.21,1.27 1.29,1.36 1.27,1.34  1.28,1.32 1.16, 1.23 1.23,1.29 1.25,1.32  1.28,1.32 1.18, 1.24 1.29,1.36 1.30,1.37  1.32,1.36  
N 128 121 108  108 124 112 111  111 138 132 117  117  
6 minute 
walk (m) 
483 538 528 
45 
(9) 
530 481 505 502 21 (4) 499 [-0.5] 466 538 541 
75 
(16) 
548 
 [0.3] 
<0.0001
‡
 
95% CI 468,499 528,553 513,544  519,541 468, 495 489,520 487,518  489,510 451-481 523,553 526,556  537,558  
N 127 118 106  106 124 109 107  107 137 129 116  116  
SF-36 
Physical 
37.3 41.6 42.4 
5 
(13) 
43.1 36.2 42.1 42.2 6 (17) 42.5 [-0.2] 36.3 43.4 45.1 
9 
(25) 
44.8 
 [-0.0] 
0.054 
95% CI 35.7,38.9 39.8,43.3 40.6,44.2  41.6,44.5 34.6, 37.9 40.3,43.8 40.5,45.0  41.1,43.9 34.8, 37.9 41.8,45.1 43.4,46.8  43.5,46.2  
N 127 118 121  121 122 112 124  124 137 131 124  124  
SF-36 
Mental 
56.7 56.2 55.4 
-1.3 
(-2) 
55.8 56.4 55.0 55.1 -1.0 (-2) 55.5 [-0.1] 57.5 57.2 56.5 
-1.0 
 (-2) 
56.0 
 [0.2] 
0.863 
95% CI 55.3,58.0 54.8,57.6 54.0,56.9  54.5,57.0 55.0, 57.9 53.6,56.5 53.7,56.6  54.3,56.7 56.4, 58.5 55.9,58.5 55.1,57.9  54.7,57.2  
N 127 118 121  121 122 112 124  124 137 131 124  124  
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eTable 3. Intention-to-treat completers-only analysis. Pairwise between group differences (mean and 95% CI) at 18-month follow-up for 
primary and secondary outcomes.  Knee compressive force and IL-6 t-tests were set at a 0.008 significance level; for secondary 
outcomes the significance level was 0.0167.  
 
 
 
 
 
 
 
 
 
 
 
*p-value from the log-adjusted variable comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Exercise vs. Diet p Exercise vs. Diet + Exercise p Diet vs. Diet + Exercise p 
Knee Comp Force N 202 (56, 348)  0.007 142 (1, 285)  0.05 -60 (-205, 86)  0.42 
IL-6 pg
.
mL
-1
 0.54 (0.11, 0.98)  0.0007* 0.50 (0.07, 0.93)  0.0007* -0.05 (-0.48, 0.38)  0.97* 
Pain 0.43 (-1.15, 0.29)  0.24 1.05 (0.33, 1.78)  0.004 1.48 (0.78, 2.18)  < 0.0001 
Function 0.04 (-2.31, 2.24) 0.97 4.21 (1.93, 6.49) 0.0003 4.25 (2.04, 6.45) 0.0002 
Walk Speed (m
.
s
-1
) 0.00 (-0.03, 0.03) 0.92 -0.04 (-0.07, -0.01) 0.01 -0.04 (-0.07, -0.01) 0.009 
6 minute walk (m) 30.5 (15.2, 45.9) 0.0001 -17.8 (-33.1, -2.6) 0.02 -48.3 (-63.1, -33.6) <0.0001 
SF-36 Physical 0.55 (-1.48, 2.58) 0.60 -1.78 (-3.82, 0.25) 0.09 -2.33 (-4.29, -0.36) 0.02 
SF-36 Mental 0.26 (-1.54, 2.06) 0.78 -0.22 (-2.04, 1.59) 0.81 -0.48 (-2.23, 1.27) 0.59 
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eTable 4:  Mean (SE) dose response to weight change with knee compressive force, IL-6, pain,  
and function independent of group assignment. 
  
% Weight Change 
Compressieve 
Force  (N) 
IL-6  (pg.ml-1) Pain Function 
High 
-32.5% to -10.1% 
2482 (44) 2.64 (0.12) 3.72 (0.28) 13.27 (0.88) 
Medium 
-9.8% to -5.0% 
2708 (47) 2.75 (0.14) 4.62 (0.29) 16.46 (0.87) 
Low 
-4.9% to 9.9% 
2842 (35) 3.07 (0.11) 4.33 (0.23) 17.17 (0.69) 
P value <0.001 0.02 0.02 0.01 
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Methods (On-line Supplemental Material)   
Knee Joint Load.  Bone-on-bone peak tibiofemoral (knee) compressive force was the primary measure of knee joint loading. A 25-reflective 
marker set, arranged in the Cleveland Clinic full-body configuration, and a 6-camera Motion Analysis (Santa Rosa, CA) system set to sample data 
at 60 Hz were used to collect 3-D kinematic data, which were tracked, edited, and smoothed, using EVaRT 4.4 software, and a Butterworth low-
pass filter with a cut-off frequency of 6 Hz. The processed data were compiled using OrthoTrak 6.0 β4 clinical gait analysis software.  
A 6-channel force platform (Advanced Mechanical Technologies, Inc., Newton, MA) was integrated with the motion capture system for 
simultaneous kinetic data collection at 480 Hz. Six successful trials were collected on each participant with 3 chosen for subsequent analysis. A 
successful trial was defined as one in which the participant’s entire foot was placed on the surface area of the force platform while walking within  
3.5% of freely chosen speed. The smoothed coordinate data, ground reaction, and gravitational and inertial forces informed an inverse dynamics 
model to calculate 3-D hip flexion and extension; knee flexion, extension, abduction, internal rotation, and external rotation; and ankle plantar- and 
dorsiflexion moments.  
 A musculoskeletal model developed by DeVita and Hortobagyi56 was used to calculate knee joint compressive force and has two basic 
components. First, joint moments and joint-reaction forces are calculated from kinematic, physiological, and force-plate data. Then they are used 
to calculate individual muscle forces and compressive and shear forces in three steps: (1) determining the forces in the gastrocnemius, 
hamstrings, and quadriceps muscles and lateral support tissues in the knee; (2) applying them along with joint-reaction forces onto the tibia; and 
(3) determining knee-joint forces. The model, its limitations, and a comparison of its predictions with other models are discussed elsewhere.22;55 
 
